If you’ve been hearing a lot about Ozempic lately, you're not alone. Once a quiet diabetes drug, it shot to fame as a weight-loss injection. But now, it might be about to earn a new title: a potential game-changer for liver disease. You read that right—Ozempic may not just help you shed pounds, but also reverse serious and common liver conditions.
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist originally designed to manage blood sugar in people with type 2 diabetes. It works by mimicking a hormone that controls hunger, making you feel full faster and eat less. That’s how it gained massive popularity for weight loss. But researchers recently discovered another potential benefit that could impact millions—its ability to tackle non-alcoholic steatohepatitis, or NASH.
NASH is an advanced form of non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver unrelated to alcohol use. Over time, that fat causes inflammation and liver cell damage, leading to fibrosis (scarring), cirrhosis, or even liver failure. There’s currently no approved drug specifically for treating it.
This is where Ozempic comes in—and it’s not just hype.
The landmark study
A new clinical trial, published in the New England Journal of Medicine , revealed that semaglutide can significantly improve liver health in NASH patients. The study was led by Dr Arun Sanyal of the Virginia Commonwealth University (US), and Dr Philip Newsome of King’s College London.
Researchers followed over 800 people diagnosed with NASH and liver fibrosis. Participants were randomly given either a weekly injection of semaglutide (Ozempic) or a placebo for 72 weeks. The results? Jaw-dropping.
More than 62.9% of patients taking semaglutide saw a complete resolution of NASH, compared to just 34.3% in the placebo group. Improvements in both MASH and fibrosis were seen in 32.7 percent of the participants on semaglutide, compared to 16.1 percent of the placebo group.
Even better? People also lost weight which is linked to liver health.
Why is this big news?
Until now, patients with NASH have been told the same old advice: lose weight, exercise more, and eat better. While lifestyle changes do work, they’re often not enough for people already dealing with fibrosis and significant liver inflammation. Plus, not everyone is able to lose the amount of weight needed to improve liver health.
With semaglutide, patients may finally have a real treatment that goes beyond just symptom management.
Should everyone with liver disease be on Ozempic?
Not so fast. While this is exciting news, semaglutide isn’t approved yet specifically for NASH or fatty liver disease—it’s currently approved for type 2 diabetes and used for weight loss.
Semaglutide, like any drug, it comes with side effects—nausea, vomiting, constipation, and possible risks for pancreatitis or gallbladder issues in some people. So, it’s not a universal fix—but it could be a huge step forward for those battling progressive liver disease with few other options, once it gets approved. Don’t make any changes without talking to your doctor.
Video
You may also like
Chelsea have just added four new players to Enzo Maresca's squad for the rest of the season
Newsboy's ITV4 selections for Chester and Huntingdon plus tips from Thursday's other meetings
Centre invites expert comments to develop India's Climate Finance Taxonomy for Net Zero goal
British bomb disposal expert killed while dismantling device in Ukraine
Stalker jailed for hellish campaign after a family evicted him from their land